Ad-hoc | 4 February 2021 19:28

Eckert & Ziegler: PENTIXAPHARM Lead Candidate PENTIXAFOR Can Go in Phase III Study, EMA says

Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Miscellaneous
Eckert & Ziegler: PENTIXAPHARM Lead Candidate PENTIXAFOR Can Go in Phase III Study, EMA says

04-Feb-2021 / 19:28 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Berlin, 04.02.2021 – Würzburg based PENTIXAPHARM GmbH, an associate of Eckert & Ziegler AG (ISIN DE0005659700), has received confirmation from the European Medicines Agency (EMA) that its lead candidate PENTIXAFOR may be tested directly in a phase III clinical study. The agency said that there are “sufficient safety data available to initiate a phase III trial” for the Gallium-68 labelled radiodiagnostic which detects CXCR4-positiv solid tumors and CXCR4-positive hematological malignancies.

Contact:
Eckert & Ziegler AG
Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel. +49 30 941084-138, karolin.riehle@ezag.de, www.ezag.de

Information and Explanation of the Issuer to this News:

Details about PENTIXAFOR and the content of the EMA advice will be provided in the next days in a separate PENTIXAPHARM press release.

04-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Eckert & Ziegler Strahlen- und Medizintechnik AG
	Robert-Rössle-Str.10
	13125 Berlin
	Germany
Phone:	+49 30 941084-138
Fax:	+49 30 941084-112
E-mail:	karolin.riehle@ezag.de
Internet:	www.ezag.de
ISIN:	DE0005659700
WKN:	565970
Indices:	SDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1166049

End of Announcement DGAP News Service